{
  "report_rows": [
    {
      "kpi": "Organic Revenue Growth (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~+3.0% vs. cons +2.57%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (Q3 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~$3.25 vs. cons $3.14",
      "confidence": "HIGH"
    },
    {
      "kpi": "Chloraprep Ship Hold Impact",
      "prediction": "BEAT",
      "answer": "pred minimal revenue impact; hold resolved or near-resolved",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 Adj. EPS (FY2026)",
      "prediction": "BETTER",
      "answer": "guide ~$12.75-$12.85 midpoint vs. cons $12.62",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 Organic Revenue Growth (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "reaffirm 'low single-digit' vs. cons ~2.5%",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 Adj. Operating Margin (FY2026)",
      "prediction": "UNCHANGED",
      "answer": "reaffirm ~25% vs. cons ~25%",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 4.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 2.5,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 strong day-1 on EPS beat + raise, then partial give-back as unchanged revenue guide and Alaris Q4 headwind are re-priced; sell-side Q4 revenue estimates drift slightly lower even as FY EPS estimates rise",
  "day5_confidence": "MEDIUM"
}